Zoetis Valuation
Is ZTS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ZTS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ZTS * (MX$2905) is trading above our estimate of fair value (MX$2402.7)
Significantly Below Fair Value: ZTS * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZTS *?
Other financial metrics that can be useful for relative valuation.
What is ZTS *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$79.07b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 9.6x |
Enterprise Value/EBITDA | 23.5x |
PEG Ratio | 3.9x |
Price to Earnings Ratio vs Peers
How does ZTS *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 27.7x | ||
LAB B Genomma Lab Internacional. de | 15.2x | 28.6% | Mex$15.9b |
MRK Merck KGaA | 26.9x | 11.6% | €73.3b |
GSK GSK | 16.2x | 12.2% | UK£72.7b |
4568 Daiichi Sankyo Company | 52.4x | 18.6% | JP¥10.5t |
ZTS * Zoetis | 33.2x | 8.6% | Mex$79.1b |
Price-To-Earnings vs Peers: ZTS * is expensive based on its Price-To-Earnings Ratio (33.2x) compared to the peer average (27.7x).
Price to Earnings Ratio vs Industry
How does ZTS *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Earnings vs Industry: ZTS * is expensive based on its Price-To-Earnings Ratio (33.2x) compared to the Global Pharmaceuticals industry average (25.3x).
Price to Earnings Ratio vs Fair Ratio
What is ZTS *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 33.2x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ZTS *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$2,893.31 | Mex$3,566.15 +23.3% | 11.0% | Mex$4,191.72 | Mex$2,873.36 | n/a | 13 |
May ’25 | Mex$2,721.00 | Mex$3,641.06 +33.8% | 10.2% | Mex$4,220.96 | Mex$2,893.40 | n/a | 16 |
Apr ’25 | Mex$2,755.15 | Mex$3,670.21 +33.2% | 9.4% | Mex$4,324.19 | Mex$2,827.36 | n/a | 16 |
Mar ’25 | Mex$3,411.40 | Mex$3,798.23 +11.3% | 8.9% | Mex$4,449.82 | Mex$2,909.50 | n/a | 16 |
Feb ’25 | Mex$3,238.50 | Mex$3,789.79 +17.0% | 9.1% | Mex$4,373.45 | Mex$2,915.64 | n/a | 16 |
Jan ’25 | Mex$3,309.55 | Mex$3,689.38 +11.5% | 10.6% | Mex$4,377.81 | Mex$2,918.54 | n/a | 15 |
Dec ’24 | Mex$3,025.56 | Mex$3,748.46 +23.9% | 10.5% | Mex$4,500.42 | Mex$3,000.28 | n/a | 14 |
Nov ’24 | Mex$2,760.00 | Mex$3,930.92 +42.4% | 10.8% | Mex$4,707.69 | Mex$3,078.11 | n/a | 15 |
Oct ’24 | Mex$2,964.61 | Mex$3,868.56 +30.5% | 10.3% | Mex$4,597.71 | Mex$3,006.20 | n/a | 15 |
Sep ’24 | Mex$3,236.00 | Mex$3,622.99 +12.0% | 11.4% | Mex$4,356.35 | Mex$2,848.38 | n/a | 13 |
Aug ’24 | Mex$3,140.00 | Mex$3,621.51 +15.3% | 12.0% | Mex$4,415.84 | Mex$2,887.28 | n/a | 13 |
Jul ’24 | Mex$2,939.00 | Mex$3,713.28 +26.3% | 12.7% | Mex$4,522.02 | Mex$2,956.71 | n/a | 12 |
Jun ’24 | Mex$2,907.10 | Mex$3,814.23 +31.2% | 12.4% | Mex$4,628.70 | Mex$3,026.46 | n/a | 12 |
May ’24 | Mex$3,106.40 | Mex$3,860.39 +24.3% | 12.5% | Mex$4,688.37 | Mex$3,065.47 | Mex$2,721.00 | 12 |
Apr ’24 | Mex$2,924.00 | Mex$3,956.59 +35.3% | 12.3% | Mex$4,786.57 | Mex$3,129.68 | Mex$2,755.15 | 12 |
Mar ’24 | n/a | Mex$3,956.59 0% | 12.3% | Mex$4,786.57 | Mex$3,129.68 | Mex$3,411.40 | 12 |
Feb ’24 | Mex$3,087.86 | Mex$3,939.05 +27.6% | 13.2% | Mex$4,696.05 | Mex$3,193.31 | Mex$3,238.50 | 12 |
Jan ’24 | Mex$2,790.00 | Mex$4,047.24 +45.1% | 14.4% | Mex$4,843.30 | Mex$3,293.44 | Mex$3,309.55 | 11 |
Dec ’23 | Mex$2,907.15 | Mex$4,047.24 +39.2% | 14.4% | Mex$4,843.30 | Mex$3,293.44 | Mex$3,025.56 | 11 |
Nov ’23 | n/a | Mex$4,471.18 0% | 10.0% | Mex$5,284.62 | Mex$3,723.26 | Mex$2,760.00 | 11 |
Oct ’23 | Mex$3,032.00 | Mex$4,603.97 +51.8% | 10.5% | Mex$5,386.76 | Mex$3,795.22 | Mex$2,964.61 | 11 |
Sep ’23 | Mex$3,182.00 | Mex$4,603.97 +44.7% | 10.5% | Mex$5,386.76 | Mex$3,795.22 | Mex$3,236.00 | 11 |
Aug ’23 | Mex$3,697.89 | Mex$4,672.80 +26.4% | 10.7% | Mex$5,456.30 | Mex$3,844.21 | Mex$3,140.00 | 11 |
Jul ’23 | Mex$3,505.00 | Mex$4,677.05 +33.4% | 10.0% | Mex$5,287.97 | Mex$3,725.62 | Mex$2,939.00 | 10 |
Jun ’23 | Mex$3,304.00 | Mex$4,719.76 +42.8% | 11.3% | Mex$5,512.46 | Mex$3,728.43 | Mex$2,907.10 | 11 |
May ’23 | n/a | Mex$4,925.82 0% | 9.0% | Mex$5,512.62 | Mex$3,728.54 | Mex$3,106.40 | 11 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.